Anti-GPC3 CAR T for Treating Patients With Advanced HCC
Phase 1
Completed
- Conditions
- Hepatocellular Carcinoma
- Registration Number
- NCT02395250
- Lead Sponsor
- RenJi Hospital
- Brief Summary
The purpose of this study is to determine whether autologous T cells bearing chimeric antigen receptor that can specifically recognize glypican-3 (GPC3) is safe and effective for patients with relapsed or refractory hepatocellular carcinoma (HCC).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 13
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Adverse events attributed to the administration of the anti-GPC3 CAR T cells 2 years
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Shanghai Cancer Institute
🇨🇳Xuhui, Shanghai, China
Shanghai Cancer Institute🇨🇳Xuhui, Shanghai, China